Clinical and biochemical comparison of clorazepate and diazepam

Robin, A. A.; Curry, Stephen H.; Whelpton, Robin

doi:10.1017/s0033291700045839

Cited by 33 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of depressed patients and normals, SRT scores discrimi nated patients and agreed with the results of psychiatrists' ratings using the Hamilton De pression Rating Scale [13]. SRT scores were also correlated with the concentration of benzodiazepam measured in the blood of anxious patients [14], Higher levels of dis tress were associated with lower concentra tions.…”

Section: Validationsupporting

confidence: 70%

Measurement of Quality of Life in Clinical Trials of Therapy

Fletcher

Bulpitt

1988

Cardiology

View full text Add to dashboard Cite

This article discusses some of the issues involved in the use of quality of life methods to evaluate treatment, primarily in trials of cardiovascular disease. The choice of aspects to measure is influenced by the severity and nature of the disease, the expected benefits and adverse effects of treatment and pragmatic considerations such as the length of the trial, and availability of the methods. The choice of specific instruments should take account of good measurement criteria such as validity and reliability, and, most importantly, sensitivity to the effects of treatment. The advantages and disadvantages of interviewer and self-completed questionnaires are discussed. The choice of respondent is primarily the patient. In some circumstances it may be appropriate to also include family members, either for their views on the patient, or for an assessment of their own quality of life as this may also be disrupted. Withdrawals are a major problem in the analysis of all trial results. The inclusion of a Health Index is one method of obtaining quality of life scores from patients who withdraw or die. The interpretation of quality of life results from trials is not simple, for example, the benefit of trial inclusion needs to be distinguished from the effect of treatment. Moreover, changes in quality of life scores should correspond to changes in the patients’ own experiences of their daily lives.

show abstract

Section: Validationsupporting

confidence: 70%

Measurement of Quality of Life in Clinical Trials of Therapy

Fletcher

Bulpitt

1988

Cardiology

View full text Add to dashboard Cite

show abstract

“…Later analysis showed that the plasma nordiazepam levels in our patient had been persistently about 10 times higher than the levels expected with regular clorazepate therapy (Robins, Curry & Whelpton, 1974) yet apart from the mild side effects of drowsiness, nystagmus and ataxia, she had remained well. The 42 h nordiazepam level was the highest recorded though the patient was apparently fully recovered by this time.…”

contrasting

confidence: 49%

Attempted Suicide With Potassium Clorazepate

Hancock

Martin

1974

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Clorazepate was clinically introduced in 1972 and is being used in several countries (Charalampous et al 1973, Holmberg and Livstedt 1972, Robin et al 1974, Percy 1975. In as much as the development of dependency and delirium symptoms has been reported previously in connection with benzodiazepines (Barten 1965, Peters, Boeters 1970, Hanna 1972, Misra 1975 it is not surprising to find that clorazepate also causes these symptoms.…”

Section: Discussionmentioning

confidence: 99%